Gilead Sciences, Inc. (NASDAQ:GILD) Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $69.55, for a total value of $3,477,500.00. Following the transaction, the director now owns 3,067,762 shares of the company’s stock, valued at $213,362,847.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Gilead Sciences stock traded up $0.14 during trading on Monday, hitting $69.58. 4,627,286 shares of the company’s stock traded hands, compared to its average volume of 7,354,939. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.47 and a quick ratio of 3.39. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54. The stock has a market capitalization of $90.02 billion, a PE ratio of 8.13, a price-to-earnings-growth ratio of -2.69 and a beta of 1.01.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. During the same period last year, the firm posted $2.27 earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.44 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be given a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.28%. Gilead Sciences’s payout ratio is 26.64%.
A number of large investors have recently made changes to their positions in GILD. Principal Financial Group Inc. boosted its position in Gilead Sciences by 5.3% in the first quarter. Principal Financial Group Inc. now owns 2,945,595 shares of the biopharmaceutical company’s stock worth $222,068,000 after purchasing an additional 148,398 shares during the last quarter. Clinton Group Inc. purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at about $537,000. IFM Investors Pty Ltd lifted its position in shares of Gilead Sciences by 45.7% during the 2nd quarter. IFM Investors Pty Ltd now owns 59,124 shares of the biopharmaceutical company’s stock valued at $4,188,000 after buying an additional 18,536 shares in the last quarter. Lynch & Associates IN lifted its position in shares of Gilead Sciences by 8.4% during the 2nd quarter. Lynch & Associates IN now owns 18,541 shares of the biopharmaceutical company’s stock valued at $1,313,000 after buying an additional 1,431 shares in the last quarter. Finally, Silverleafe Capital Partners LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at about $285,000. 78.09% of the stock is currently owned by institutional investors and hedge funds.
GILD has been the subject of several analyst reports. Piper Jaffray Companies set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, September 12th. Mizuho reaffirmed a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research report on Friday, August 10th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Wednesday, July 18th. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, Evercore ISI reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Thirteen research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $87.84.
COPYRIGHT VIOLATION NOTICE: “John C. Martin Sells 50,000 Shares of Gilead Sciences, Inc. (GILD) Stock” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/05/john-c-martin-sells-50000-shares-of-gilead-sciences-inc-gild-stock.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Fundamental Analysis
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.